Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 1/2017

01-02-2017 | Erratum

Erratum to: Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)

Authors: Mario Scartozzi, Loic Vincent, Marielle Chiron, Stefano Cascinu

Published in: Targeted Oncology | Issue 1/2017

Login to get access

Excerpt

Erratum to: Targ Oncol (2016) 11:489–500 …
Metadata
Title
Erratum to: Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)
Authors
Mario Scartozzi
Loic Vincent
Marielle Chiron
Stefano Cascinu
Publication date
01-02-2017
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 1/2017
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-016-0473-2

Other articles of this Issue 1/2017

Targeted Oncology 1/2017 Go to the issue

Original Research Article

Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review

Review Article

Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma

Systematic Review

mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review

Original Research Article

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

Original Research Article

Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma

Original Research Article

Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits